Aberdeen Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Aberdeen Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5M	Buy	94,946 +15,589	+20%	+$1.41M	0.01%	585
2026 Q1	$6.9M	Buy	+79,357	New	+$7.72M	0.01%	653
2025 Q4	–	Sell	-26,740	Closed	-$2.7M	–	984
2025 Q3	$2.7M	Sell	26,740 -40,917	-60%	-$3.8M	﹤0.01%	752
2025 Q2	$4.28M	Sell	67,657 -40,472	-37%	-$2.48M	0.01%	721
2025 Q1	$5.73M	Buy	108,129 +27,612	+34%	+$1.53M	0.01%	667
2024 Q4	$4.51M	Sell	80,517 -32,287	-29%	-$1.78M	0.01%	667
2024 Q3	$5.91M	Hold	112,804	–	–	0.01%	623
2024 Q2	$4.63M	Buy	+112,804	New	+$4.5M	0.01%	641
2019 Q2	–	Sell	-21,523	Closed	-$590K	–	936
2019 Q1	$590K	Buy	+21,523	New	+$619K	﹤0.01%	847

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aberdeen Group's RYTM Position: Q2 2026 in Review

Aberdeen Group increased its Rhythm Pharmaceuticals (RYTM) stake by 20% in Q2 2026, buying an estimated $1.41M and bringing the position to 94,946 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #585.

Aberdeen Group first reported a position in RYTM in Q1 2019 and has held it in 9 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Aberdeen Group held 94,946 shares of Rhythm Pharmaceuticals worth $10.5M as of Q2 2026.
Aberdeen Group bought 15,589 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
Rhythm Pharmaceuticals made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #585 holding.
Aberdeen Group first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.